The House of Lords Science and Technology Committee continues taking evidence for its inquiry into Life Sciences and the Industrial Strategy.
Purpose of sessions
Lord Heseltine recently said that an effective industrial strategy should “stimulate a culture of enterprise throughout our society”. The Committee hears Lord Heseltine’s views on how life sciences can contribute to this objective and make the industrial strategy a success.
Then Genomics England and the Royal Society give their views on how the Life Sciences Industrial Strategy’s recommendations on the exploitation of health data should be implemented in order to maximise economic and health benefits to the UK.
Finally, the Committee question the Chief Medical Officer for England and the Department of Health Chief Scientific Adviser on whether the NHS is equipped to provide the level of innovation needed to implement the Life Sciences Industrial Strategy.
Tuesday 21 November in Committee Room 4A, Place of Westminster
- The Rt Hon the Lord Heseltine CH
- Sir John Chisholm, Executive Chair, Genomics England
- Professor Dame Ottoline Leyser, Royal Society
At 12 noon
- Professor Dame Sally Davies, Chief Medical Officer for England
- Professor Chris Whitty, DH Chief Scientific Adviser, interim Government Chief Scientific Adviser
Questions likely to be covered in the sessions include:
- Much of the data within the NHS are held in different forms and in separate systems that cannot always talk to each other. How can these technical challenges be overcome?
- How do we ensure that the UK workforce has the necessary skills to make sure Sir John Bell's strategy is a success?
- Is a life sciences strategy of this kind and a 'sector deal' the best way of optimising the relationship between Government and business?
- Who should be responsible for implementing the Life Sciences Industrial Strategy and to whom should they be accountable?
Image: Parliamentary copyright